CYBER SECURITY
BACK TO CONTENTS
FOCUS 4
A 360° VIEW OF CYBER SECURITY
KEEPING YOUR PRIZE ASSETS SAFE
By GILES WATKINS & MARK THOMPSON
Pharmaceutical companies need to take a proactive and systematic approach in order to win the battle against cybercrime and keep their key information assets protected.
M
anaging IT security in a pharmaceutical and life sciences company these days can sometimes feel like putting out a fi re that keeps
on fl aring up again somewhere else. Where once it was possible to construct a protective boundary around the organisation, data now fl ows in a myriad of directions to multiple third parties responsible for clinical trials, Human
Resources (HR), fi nance, analytics, customer relationship management (CRM) and customer service, as well as to vendors, suppliers and the healthcare profession.
Having grown swiftly through acquisition, the bigger pharma fi rms often have a plethora of unintegrated systems, making it much harder to oversee defences. At the same time, the volume of data generated by research,
© 2014 KPMG LLP, a UK limited liability partnership, and a member fi rm of the KPMG network of independent member fi rms affi liated with KPMG International Cooperative, a Swiss entity. All rights reserved.
production and marketing is continually rising, to previously unforeseen levels. The growth in work with third parties through JVs and other initiatives has led to the number of contact points with the outside world increasing signifi cantly– which itself increases the external threat. It is no longer possible for a company to simply erect a wall around its systems in order to stay protected; some might argue that this walled defence approach was always an illusion,
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41